Reading view
Beyond Monolithic Architectures: A Multi-Agent Search and Knowledge Optimization Framework for Agentic Search
Decision-Aware Trust Signal Alignment for SOC Alert Triage
PILOT-Bench: A Benchmark for Legal Reasoning in the Patent Domain with IRAC-Aligned Classification Tasks
Smart IoT-Based Wearable Device for Detection and Monitoring of Common Cow Diseases Using a Novel Machine Learning Technique
Belief in Authority: Impact of Authority in Multi-Agent Evaluation Framework
Atlas 2 -- Foundation models for clinical deployment
PsychEval: A Multi-Session and Multi-Therapy Benchmark for High-Realism AI Psychological Counselor
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
Medicaid restrictions may lead to a million missed cancer screenings over two years: study
In less than a year, new Medicaid eligibility restrictions may lead millions of people to lose coverage and then miss potentially lifesaving cancer screenings like colonoscopies or mammograms. A new analysis estimates that Americans may miss more than a million cancer screenings for colorectal, breast, or lung cancer over the two years after the new policy takes effect.
“I see patients every day that come to me with cancer and are asymptomatic, but their life gets turned upside down because they are told they have cancer,” said Adrian Diaz, a surgical oncologist at the University of Chicago and one of the authors on the paper, published Thursday in JAMA Oncology. “In a positive way, we catch it early. It’s potentially treatable, curable. Seeing that number, over a million patients, who will not have that opportunity — I was taken aback.”


© ASHRAF SHAZLY/AFP via Getty Images
A Web-Based Cancer Prevention Intervention for Rural Emerging Adults: Mixed Methods Development and Pilot-Testing Study
Leveraging Genetic Instrumental Variables and Sequencing Analysis to Identify a Prognostic Signature Based on Epithelial Cell Markers in Lung Adenocarcinoma
Thorac Cancer. 2026 Jan;17(1):e70244. doi: 10.1111/1759-7714.70244.
ABSTRACT
MAIN PROBLEM: The treatment and prognosis of lung adenocarcinoma (LUAD) remain challenging. The study aimed to identify prognostic genes and construct a prognostic model for LUAD.
METHODS: After identifying malignant alveolar type II (AT2) cells using InferCNV, we applied CytoTRACE, pseudo-time analysis, Mendelian randomization (MR), and univariate Cox regression analysis to identify prognostic genes. A prognostic model was then developed using an optimized subset of these genes, selected through the least absolute shrinkage and selection operator (LASSO) algorithm. Further analyses included Gene Ontology enrichment analysis and the construction of a protein-protein interaction (PPI) network.
RESULTS: Pseudo-time analysis identified 3526 dynamically expressed genes during malignant AT2 cell dedifferentiation. Subsequent multi-omics integration refined the gene selection, yielding four prognostic genes for the final predictive model. The resulting model achieved area under the receiver operating characteristic (ROC) curve (AUC) values of 0.649, 0.675, and 0.654 for predicting 1, 2, and 3-year overall survival (OS) in the training set, respectively, and was successfully validated in two external cohorts at the corresponding time points. Moreover, survival analysis demonstrated that patients in the high-risk group had significantly poorer OS than those in the low-risk group, both in the training set and the validation sets (p < 0.01).
CONCLUSIONS: The study developed a novel signature based on genes dynamically expressed during malignant AT2 cell dedifferentiation, capable of predicting the prognosis of LUAD patients, and offered four accurate prognostic biomarkers (ADM, MARK4, PARVA, and RPS6KA1).
PMID:41500831 | DOI:10.1111/1759-7714.70244
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
npj Digital Medicine, Published online: 07 January 2026; doi:10.1038/s41746-025-02324-4
An autonomous agentic workflow for clinical detection of cognitive concerns using large language modelsFactors Influencing Continuance Intention for Online Consultations Among Survivors of Cancer: Grounded Theory Study
Deploying a hybrid approach to Web3 in the AI era
When the concept of “Web 3.0” first emerged about a decade ago the idea was clear: Create a more user-controlled internet that lets you do everything you can now, except without servers or intermediaries to manage the flow of information.
Where Web2, which emerged in the early 2000s, relies on centralized systems to store data and supply compute, all owned—and monetized by—a handful of global conglomerates, Web3 turns that structure on its head. Instead, data and compute are decentralized through technologies like blockchain and peer-to-peer networks.

What was once a futuristic concept is quickly becoming a more concrete reality, even at a time when Web2 still dominates. Six out of ten Fortune 500 companies are exploring blockchain-based solutions, most taking a hybrid approach that combines traditional Web2 business models and infrastructure with the decentralized technologies and principles of Web3.
Popular use cases include cloud services, supply chain management, and, most notably financial services. In fact, at one point, the daily volume of transactions processed on decentralized finance exchanges exceeded $10 billion.
Gaining a Web3 edge
Among the advantages of Web3 for the enterprise are greater ownership and control of sensitive data, says Erman Tjiputra, founder and CEO of the AIOZ Network, which is building infrastructure for Web3, powered by decentralized physical infrastructure networks (DePIN), blockchain-based systems that govern physical infrastructure assets.
More cost-effective compute is another benefit, as is enhanced security and privacy as the cyberattack landscape grows more hostile, he adds. And it could even help protect companies from outages caused by a single point of failure, which can lead to downtime, data loss, and revenue deficits.
But perhaps the most exciting opportunity, says Tjiputra, is the ability to build and scale AI reliably and affordably. By leveraging a people-powered internet infrastructure, companies can far more easily access—and contribute to—shared resource like bandwidth, storage, and processing power to run AI inference, train models, and store data. All while using familiar developer tooling and open, usage-based incentives.
“We’re in a compute crunch where requirements are insatiable, and Web3 creates this ability to benefit while contributing,” explains Tjiputra.
In 2025, AIOZ Network launched a distributed compute platform and marketplace where developers and enterprises can access and monetize AI assets, and run AI inference or training on AIOZ Network’s more than 300,000 contributing devices. The model allows companies to move away from opaque datasets and models and scale flexibly, without centralized lock in.
Overcoming Web3 deployment challenges
Despite the promise, it is still early days for Web3, and core systemic challenges are leaving senior leadership and developers hesitant about its applicability at scale.
One hurdle is a lack of interoperability. The current fragmentation of blockchain networks creates a segregated ecosystem that makes it challenging to transfer assets or data between platforms. This often complicates transactions and introduces new security risks due to the reliance on mechanisms such as cross-chain bridges. These are tools that allow asset transfers between platforms but which have been shown to be vulnerable to targeted attacks.
“We have countless blockchains running on different protocols and consensus models,” says Tjiputra. “These blockchains need to work with each other so applications can communicate regardless of which chain they are on. This makes interoperability fundamental.”
Regulatory uncertainty is also a challenge. Outdated legal frameworks can sit at odds with decentralized infrastructures, especially when it comes to compliance with data protection and anti-money laundering regulations.
“Enterprises care about verifiability and compliance as much as innovation, so we need frameworks where on-chain transparency strengthens accountability instead of adding friction,” Tjiputra says.
And this is compounded by user experience (UX) challenges, says Tjiputra. “The biggest setback in Web3 today is UX,” he says. “For example, in Web2, if I forget my bank username or password, I can still contact the bank, log in and access my assets. The trade-off in Web3 is that, should that key be compromised or lost, we lose access to those assets. So, key recovery is a real problem.”
Building a bridge to Web3
Although such systemic challenges won’t be solved overnight, by leveraging DePIN networks, enterprises can bridge the gap between Web2 and Web3, without making a wholesale switch. This can minimize risk while harnessing much of the potential.
AIOZ Network’s own ecosystem includes capacity for media streaming, AI compute, and distributed storage that can be plugged into an existing Web2 tech stack. “You don’t need to go full Web3,” says Tjiputra. “You can start by plugging distributed storage into your workflow, test it, measure it, and see the benefits firsthand.”
The AIOZ Storage solution, for example, offers scalable distributed object storage by leveraging the global network of contributor devices on AIOZ DePIN. It is also compatible with existing storage systems or commonly used web application programming interfaces (APIs).
“Say we have a programmer or developer who uses Amazon S3 Storage or REST APIs, then all they need to do is just repoint the endpoints,” explains Tjiputra. “That’s it. It’s the same tools, it’s really simple. Even with media, with a single one-stop shop, developers can do transcoding and streaming with a simple REST API.”
Built on Cosmos, a network of hundreds of different blockchains that can communicate with each other, and a standardized framework enabled by Ethereum Virtual Machine (EVM), AIOZ Network has also prioritized interoperability. “Applications shouldn’t care which chain they’re on. Developers should target APIs without worrying about consensus mechanisms. That’s why we built on Cosmos and EVM—interoperability first.”
This hybrid model, which allows enterprises to use both Web2 and Web3 advantages in tandem, underpins what Tjiputra sees as the longer-term ambition for the much-hyped next iteration of the internet.
“Our vision is a truly peer-to-peer foundation for a people-powered internet, one that minimizes single points of failure through multi-region, multi-operator design,” says Tjiputra. “By distributing compute and storage across contributors, we gain both cost efficiency and end-to-end security by default.
“Ideally, we want to evolve the internet toward a more people-powered model, but we’re not there yet. We’re still at the starting point and growing.”
Indeed, Web3 isn’t quite snapping at the heels of the world’s Web2 giants, but its commercial advantages in an era of AI have become much harder to ignore. And with DePIN bridging the gap, enterprises and developers can step into that potential while keeping one foot on surer ground.
To learn more from AIOZ Network, you can read the AIOZ Network Vision Paper.
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff.
This content was researched, designed, and written by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.
Adaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment
Transl Oncol. 2026 Jan 6;64:102660. doi: 10.1016/j.tranon.2025.102660. Online ahead of print.
ABSTRACT
Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. The low rate of early diagnosis and the high rate of occult metastases limit the survival benefits of conventional treatments. The current TNM staging system fails to fully reflect tumor heterogeneity or the dynamic molecular evolution of the disease, thus affecting the prediction of recurrence and the prognostic stratification. Some recent advances in minimal residual disease (MRD) detection, such as ultra-sensitive liquid biopsy technologies, have largely overcome the limitations of traditional imaging and offered a transformative approach for continuous, precision-based management of lung cancer. This review systematically summarized the technological evolution of MRD detection and highlighted its clinical significance in guiding adaptive therapy for NSCLC, including treatment escalation, de-escalation, and the emerging concept of precision-guided drug holidays. Moreover, the authors comprehensively discussed the "Four-Dimensional TNMB Staging System," which incorporates continuous molecular monitoring to address the static limitations of conventional staging and enhance the accuracy of prognostic stratification. Although ongoing challenges, such as the lack of standardized interpretation criteria and limited detection sensitivity, the combinations with the third-generation liquid biopsy platforms, multi-omics analyses, and multi-center prospective validation studies are expected to advance the clinical implementation of MRD-guided strategies. The paradigm change will enable the transition of NSCLC management from conventional standardized models to a precision-guided, closed-loop system of "monitoring-intervention-remonitoring," establishing a solid theoretical and practical foundation for comprehensive, molecularly driven management strategies.
PMID:41496417 | DOI:10.1016/j.tranon.2025.102660
Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine
J Transl Med. 2026 Jan 6. doi: 10.1186/s12967-025-07596-8. Online ahead of print.
ABSTRACT
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of < 13%. Standard treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel yield modest response rates, underscoring the urgent need for precision oncology approaches. Patient-derived organoids (PDOs) preserve the genomic, phenotypic, and histopathological features of the source tumor and offer a promising platform for drug screening, biomarker development, and personalized therapy. However, a systematic evaluation of their translational capacities is lacking.
METHODS: A systematic review was conducted according to the PRISMA 2020 guidelines (PROSPERO registration pending) using PubMed, EMBASE, and Cochrane CENTRAL (December 10, 2024) to identify English-language PDAC PDO studies that incorporated therapeutic testing. Ninety-five studies met the inclusion criteria. Data extraction captured >75 variables per study, including spanning culture methodology, therapeutic profiling, biomarker integration, and clinical correlation. A 13-domain weighted Translatability Scoring Framework adapted from Wehling et al. assessed predictive validity, biomarker strength, pharmacogenetics, and clinical trial alignment. Scores ranged from 0 to 5 and were categorized as good (>4.0), moderate (3.0-4.0), or low (<3.0) translational potential.
RESULTS: Of the 95 studies, 70.5% have been published since 2021, reflecting the rapid growth in this field. The mean PDO generation success rate was 89.7%, with the primary tumor tissue being the predominant source (48.4%). Only 24.8% were directly linked to clinical trials and 5.3% incorporated multi-omic profiling. The median translatability score was 3.13 (range, 1.72-4.59): 45.3% of the studies had low translatability, 50.5% moderate, and only 4.2% had good translational potential. High-scoring studies consistently combine multi-omic biomarker platforms, in vivo validation, clinical outcome correlation, and prospective trial integration. Conversely, the weakest domains were pharmacogenetics, endpoint strategies, and biomarker validation, limiting their overall clinical relevance.
CONCLUSIONS: PDOs have demonstrated strong feasibility and in vitro clinical correlation in PDAC; however, their clinical translation remains constrained by limited multi-omic integration, absence of pharmacogenomic modeling, and sparse clinical trial embedding. Standardization of protocols, adoption of harmonized and clinically relevant endpoints, and systematic incorporation of biomarker-driven co-clinical trial frameworks are urgently needed to transition PDOs from promising experimental surrogates to validating precision oncology tools capable of informing therapeutic decision-making in PDAC.
PMID:41495743 | DOI:10.1186/s12967-025-07596-8